ArticleAnnals of surgical oncology2026
Impact of Neoadjuvant Immunotherapy Combined with Chemotherapy on Surgical Margin Strategy in Central Non-Small-Cell Lung Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe CheckMate 816 trial showed that neoadjuvant immunotherapy combined with chemotherapy improved pathological complete response and tumor downstaging compared with chemotherapy alone. Whether this permits less extensive resection, such as reduced margins, without compromising survival remains unclear.
methodsWe included 142 patients with central-type non-small-cell lung cancer (NSCLC) who received neoadjuvant chemoimmunotherapy at three hospitals between 2017 and 2022. All were initially considered candidates for sleeve lobectomy (SLT) based on pretreatment findings. After treatment, patients with residual disease confined to the segmental bronchus and/or distal pulmonary parenchyma were considered eligible for lobectomy (LT). Patients underwent SLT or LT according to pretreatment or post-treatment tumor extent, respectively. Negative margins were confirmed by intraoperative frozen-section pathology. Propensity score weighting (PSW) was used to balance baseline characteristics.
resultsOf the 142 enrolled patients, 86 had a radiographic response, with bronchoscopy revealing tumor regression to the segmental bronchus or more proximal airways. Ultimately, 82 patients underwent surgery, seven of whom were lost to follow-up during the follow-up period. Among 75 patients, 30 (40.0%) underwent SLT and 45 (60.0%) converted to LT. Grade II-V complications occurred in one case (2.22%) in the LT group and seven cases (23.3%) in the SLT group (relative risk 0.09; 95% confidence interval 0.01-0.57; p < 0.05). After PSW, baseline characteristics were balanced between groups (p > 0.05). PSW-adjusted event-free survival showed no significant difference between groups (hazard ratio 0.53; 95% confidence interval 0.13-2.22; p > 0.05).
conclusionFor central-type NSCLC initially planned for SLT, conversion to LT is feasible when adequate negative margins are confirmed after neoadjuvant chemoimmunotherapy, potentially avoiding more extensive surgery.
Indexed as
Identifiers
42825882What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.